While some patients report improvements in energy and body composition, the evidence for direct weight loss is limited and far weaker than what exists for GLP-1 receptor agonists
DR10627-family, XGLP/GCG/GIP-32 (Guangxi Medical University / Jiangsu Normal University), TRA24 (Henan University of Technology / Chia Tai Tianqing / Shanghai Duomirui), PB-2309 (PegBio), PN-477 (Protagonist Therapeutics), CS-14 and CS-120070 (Cascade Pharmaceuticals, peptide and small-molecule respectively), FD1016 (Suzhou Yihe), UTG-4 (Guangzhou University of Chinese Medicine), XFL6 (Xi'an Jiaotong First Affiliated Hospital), RAY-0221 (Raynovent, small molecule) - a long tail of Chinese preclinical programs, predominantly peptide-format, mostly targeting obesity with secondary positioning in type 2 diabetes and MASH
In Sherman, Texas, were here to support you every step of the way
It affects: How you get new patients How you screen and evaluate them How you document care How you order, stock, and track meds How you communicate with patients Patient Leads and Advertising The FDAs 2026 warning letters targeted clinics and telehealth companies for using phrases like same active ingredient as Ozempic, generic Zepbound, or from the same family as Mounjaro. If you've got anything like that on your website or in your ads, take it down
Tirzepatide: A dual-agonist